Wall Street Zen Upgrades PAVmed (NASDAQ:PAVM) to “Hold”

PAVmed (NASDAQ:PAVM) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other analysts also recently issued reports on the company. Weiss Ratings restated a “sell (d)” rating on shares of PAVmed in a research report on Thursday, January 22nd. Ascendiant Capital Markets reduced their target price on shares of PAVmed from $600.00 to $510.00 and set a “buy” rating on the stock in a research note on Wednesday, December 10th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $510.00.

PAVmed Price Performance

Shares of PAVM stock opened at $9.85 on Friday. The company has a market cap of $9.85 million, a PE ratio of -0.43 and a beta of 0.81. PAVmed has a 1 year low of $6.00 and a 1 year high of $28.44. The stock’s 50 day simple moving average is $9.90 and its two-hundred day simple moving average is $10.59.

Hedge Funds Weigh In On PAVmed

An institutional investor recently raised its position in PAVmed stock. Geode Capital Management LLC lifted its position in PAVmed Inc. (NASDAQ:PAVM) by 74.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 168,832 shares of the company’s stock after acquiring an additional 72,258 shares during the quarter. Geode Capital Management LLC owned 17.23% of PAVmed worth $40,000 as of its most recent SEC filing. Institutional investors own 19.93% of the company’s stock.

PAVmed Company Profile

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.